Researchers conducted a phase 3 trial to ascertain whether treatment regimens including rifapentine with or without moxifloxacin can provide a lasting cure for drug-susceptible pulmonary tuberculosis in 4 months vs 6 months of standard therapy.
Researchers compared the antibody responses of 2 age groups, one younger than 60 years and one older than 80 years, to the first and second doses of the Pfizer-BioNTech COVID-19 vaccination.
A team of investigators sought to estimate the burden of acute respiratory illness in ambulatory care settings for 12 respiratory viruses in Washington state during the 2018-2019 influenza season.
Investigators conducted a systematic review and meta-analysis of 37 studies that used a test-negative design to evaluate IVE against influenza-associated hospitalization in children.
Study authors evaluated the safety and efficacy of intravenous immunoglobulin plus the standard of care in the treatment of COVID-19 patients with moderate pneumonia.
Study authors evaluated the safety and efficacy of intravenous immunoglobulin plus the standard of care in the treatment of COVID-19 patients with moderate pneumonia.
An interim phase 3 trial shows promising results for the Russian heterologous recombinant adenovirus-based SARS-CoV-2 vaccine.
Study authors conducted a retrospective study to determine the anti-SARS-CoV-2 IgG antibody levels in convalescent plasma used to treat hospitalized patients with COVID-19.
Study authors investigated the association between HIV diagnosis and COVID-19 diagnosis, hospitalization, and death in New York State.
The acceleration of the COVID-19 pandemic continues to stress health care systems and exacerbate disparities in many communities, highlighting the importance of identifying patients at elevated risk of severe disease for COVID-19 vaccine prioritization.
